Churchill Management’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-6,205
Closed -$903K 160
2024
Q3
$903K Sell
6,205
-1,054
-15% -$153K 0.01% 138
2024
Q2
$996K Sell
7,259
-832
-10% -$111K 0.01% 141
2024
Q1
$1.11M Sell
8,091
-609
-7% -$83.2K 0.01% 143
2023
Q4
$1.18M Sell
8,700
-1,559
-15% -$190K 0.02% 128
2023
Q3
$1.25M Sell
10,259
-15,458
-60% -$1.97M 0.02% 132
2023
Q2
$3.27M Sell
25,717
-5,697
-18% -$740K 0.06% 108
2023
Q1
$4.06M Sell
31,414
-6,672
-18% -$873K 0.08% 100
2022
Q4
$5M Sell
38,086
-6,974
-15% -$901K 0.12% 84
2022
Q3
$5.27M Buy
+45,060
New +$5.6M 0.14% 84
2021
Q4
Sell
-61,463
Closed -$9.94M 145
2021
Q3
$9.94M Sell
61,463
-4,012
-6% -$675K 0.15% 80
2021
Q2
$10.7M Sell
65,475
-6,551
-9% -$1.01M 0.16% 83
2021
Q1
$10.8M Sell
72,026
-1,137,326
-94% -$181M 0.18% 70
2020
Q4
$183M Buy
1,209,352
+21,366
+2% +$3.05M 3.12% 11
2020
Q3
$161M Sell
1,187,986
-415,853
-26% -$56.4M 3.95% 11
2020
Q2
$219M Buy
1,603,839
+1,557,575
+3,367% +$199M 6.81% 4
2020
Q1
$4.99M Buy
46,264
+1,028
+2% +$118K 0.25% 65
2019
Q4
$5.45M Buy
+45,236
New +$5.05M 0.1% 88
2018
Q1
Sell
-1,801,330
Closed -$192M 132
2017
Q4
$192M Buy
1,801,330
+129,538
+8% +$13.8M 4.22% 9
2017
Q3
$186M Buy
1,671,792
+161,556
+11% +$17.3M 4.57% 8
2017
Q2
$156M Buy
+1,510,236
New +$149M 4.08% 8
2015
Q3
Sell
-1,005,534
Closed -$124M 149
2015
Q2
$124M Sell
1,005,534
-50,538
-5% -$6.05M 4.4% 6
2015
Q1
$121M Sell
1,056,072
-19,467
-2% -$2.15M 4.15% 7
2014
Q4
$109M Sell
1,075,539
-223,296
-17% -$21.7M 4.32% 7
2014
Q3
$118M Sell
1,298,835
-485,040
-27% -$42.6M 4.87% 5
2014
Q2
$153M Buy
1,783,875
+49,029
+3% +$3.86M 6.9% 3
2014
Q1
$137M Sell
1,734,846
-38,175
-2% -$3.18M 5.37% 4
2013
Q4
$134M Buy
1,773,021
+6,903
+0.4% +$490K 5.15% 7
2013
Q3
$123M Sell
1,766,118
-56,427
-3% -$3.7M 6.36% 7
2013
Q2
$106M Buy
+1,822,545
New +$105M 4.93% 8

Other funds holding IBB

Churchill Management's IBB Position: Q4 2024 in Review

Churchill Management sold out of iShares Biotechnology ETF (IBB) in Q4 2024, closing a stake of 6,205 shares — an estimated $903K sold.

Churchill Management first reported a position in IBB in Q2 2013 and held it in 29 quarters. The position peaked at $219M in Q2 2020. 874 funds tracked by Wall St. Rank hold IBB as of Q4 2024.

  • Churchill Management reported no remaining iShares Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
  • Churchill Management sold 6,205 iShares Biotechnology ETF shares in Q4 2024, an estimated $903K.
  • Churchill Management first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 29 quarters.
  • Churchill Management's iShares Biotechnology ETF position peaked at $219M in Q2 2020.
  • 874 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2024.

Based on Churchill Management's 13F filing for Q4 2024, filed 14 Jan 2025.